Page last updated: 2020 08 11
As the world leader in Transplant Diagnostics, One Lambda is partnering with transplant professionals around the world to facilitate testing in the face of new challenges and to launch innovative research that may shed light on the immune response in COVID-19 patients.
Avoid TRALI risk by screening for HLA and HNA antibodiesFast and effective HLA and HNA antibody screening is critical for mitigating the risk of TRALI and improving the safety of convalescent plasma therapy for treating COVID-19. One Lambda’s LABScreen™ Multi solution offers the only FDA-cleared assay for the simultaneous detection of HLA and HNA specific antibodies.
|
Detect COVID-19 Antibodies for a More Complete Antibody ProfileResearch has found that pathogen infections similar to COVID-19 can lead to the development of HLA antibodies. With multiple distinct antigens and fragments, the LABScreen™ COVID Plus assay is more specific than current assays and, in combination with HLA antibody detection, can help provide a more complete picture of the patient’s antibody profile.
|
Coordinate remote DSA sample collection for your patientsUnfortunately, many transplant patients are avoiding regularly scheduled visits to testing centers during the COVID-19 pandemic. One Lambda has been working on coordinating an at-home specimen collection service to be available to patients who prefer to continue their post-transplant testing plan without traveling to a blood collection site.
|
At One Lambda, our mission is to help our customers improve the lives of transplant patients and their families. Now, more than ever, we are focused on ensuring that transplant patients are matched and monitored with the very best diagnostic solutions.
In conjunction with Thermo Fisher Scientific, we are monitoring this global situation on a 24-hour basis. We are happy to report that currently there has been no impact to our business and our ability to deliver the One Lambda-branded and Thermo Scientific products that you need to better care for your patients. Furthermore, we are working with our global channel partners to ensure that our customers outside of North America continue to have access to our products and support.
We understand that this is a very fluid situation and events can change in a matter of hours. Please be assured that all our global customers will be notified should there be any impact to our business. View our most recent Covid-19 update ❯
Most importantly, please know that as long as there are patients to be served, we are here to serve you and support you.
Here you’ll find the latest news and resources on how COVID-19 may impact the field of transplantation and may transform our understanding of both genotyping and antibody detection.
Would you like to submit a resources that you think may be of interest to the transplant community? Submit Covid-19 Transplant Resource or Comment ❯
